Evidence map›Paper›PMID 40854131›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Loss of ICOSL expression in the progression to cervical carcinoma.

Gerard J Nuovo, Esmerina Tili, Carlo M Croce

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Loss of ICOSL expression in the progression to cervical carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gerard J NuovoGNOME, Inc., Powell, OH 43065.
Esmerina TiliDepartment of Anaesthesiology, Wexner Medical Center, College of Medicine, The Ohio State University, Columbus, OH 43210.
Carlo M CroceDepartment of Cancer Biology and Genetics, Wexner Medical Center, College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210.ORCID 0000-0003-3788-1457

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
CLL Global Research Foundation (CLLGRF) AWD-115284CLL Global Research Foundation (CLLGRF) AWD-116510NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Human papillomavirus (HPV)-related lesions contain types with benign outcomes and those with a risk of progression to cancer. We addressed the role of immune surveillance in 76 cervical biopsies (normal = 23, HPV+ benign = 16, HPV+ precancer = 37) by studying the infiltration of cytotoxic T cells and the expression of the immune modulators PDL1, ICOSL, and

Indexed as

Carcinoma, Squamous CellInducible T-Cell Co-Stimulator LigandUterine Cervical NeoplasmsAdultB7-H1 AntigenDisease ProgressionFemaleGene Expression Regulation, NeoplasticGranzymesHumansMicroRNAsMiddle AgedPapillomavirus InfectionsB7-H1 AntigenCD274 protein, humanGranzymesICOSLG protein, humanInducible T-Cell Co-Stimulator LigandMicroRNAsMIRN155 microRNA, humanHPVICOSLmicroRNAPDL1SIL

Identifiers

PMID40854131
PMCPMC12415218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.